Alzheimer's disease

Pharmaceutical Journal

Volumn 264, Issue 7099, 2000, Pages 846-850

  Jones, Roy ^a  

^a St Martin's Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIRACETAM; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; GINKGO BILOBA EXTRACT; NAFTIDROFURYL OXALATE; OXIRACETAM; PIRACETAM; PRAMIRACETAM; RIVASTIGMINE; SABELUZOLE; TACRINE;

ALZHEIMER DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; MORTALITY; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY;

EID: 0034600477     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Lishman WA. Organic Psychiatry. Oxford: Blackwell Scientific Publications, 1978.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington DC: APA 1994.
3. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154 (5 Suppl):1-39.
4. Jagger C, Andersen K, Breteler MMB, Copeland JRM, Dartigues J-F, Di Carlo A, et al. Prognosis with dementia: results from a European collaborative analysis of population-based studies. In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM, editors. Alzheimer's disease and related disorders. Chichester: Wiley; 1999:39-44.
5. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software 1999.
6. Flicker L, Evans JG. Piracetam for dementia or cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software 1999.
7. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996;47:876-83.
8. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50;136-45.
9. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8: 67-75.
10. Allen H. Anti-dementia drugs. Int J Geriat Psychiatry 1999;14:239-43.
11. Matthews HP, Jorbey J, Wilkinson DG, Rowden J. Donepezil in the treatment of Alzheimer's disease: results from the first 18 months of a study in clinical practice in the UK. Eur Neuropsychopharmacol 1999;9(Suppl 5): S327.
12. Corey-Bloom J, Anand R, Veach J for the ENA713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Ger Psychopharmacol 1998;1:55-65.
13. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international, randomised controlled trial. BMJ 1999;318:633-40.
14. Harvey RJ. A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease. Int J Geriat Psychiatry 1999;14:249-56.
15. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.